绝经激素治疗与卵巢癌及子宫内膜癌:妇女健康倡议随机试验的长期随访
在妇女健康倡议两项随机安慰剂对照试验的20年随访中,单纯结合马雌激素(CEE)较安慰剂显著增加卵巢癌发病率和死亡率,而CEE联合醋酸甲羟孕酮(MPA)未增加卵巢癌发病率或死亡率,但显著降低子宫内膜癌发病率。
要点
- 单纯CEE较安慰剂显著增加卵巢癌发病率(HR 2.04,95%CI 1.14-3.65;P=0.014)和卵巢癌死亡率(P=0.006)。
- CEE联合MPA较安慰剂未增加卵巢癌发病率(HR 1.14,95%CI 0.82-1.59;P=0.44)或卵巢癌死亡率。
- CEE联合MPA较安慰剂显著降低子宫内膜癌发病率(HR 0.72,95%CI 0.56-0.92;P=0.01)。
核心结论
- 在随机临床试验中,单纯CEE增加卵巢癌发病率和卵巢癌死亡率,而CEE联合MPA未增加。
- 相比之下,CEE联合MPA显著降低子宫内膜癌发病率。
研究设计与样本
- 妇女健康倡议随机、安慰剂对照临床试验的长期随访,纳入50-79岁绝经后女性。
- 有子宫的16,608例女性中,8,506例随机接受每日一次0.625 mg CEE联合每日一次2.5 mg MPA,8,102例接受安慰剂。
- 既往子宫切除的10,739例女性中,5,310例随机接受每日一次0.625 mg单纯CEE,5,429例接受安慰剂。
- 干预在计划8.5年干预前因故停止:CEE联合MPA组于5.6年后停止,单纯CEE组于7.2年后停止。
主要发现
- 20年随访后,单纯CEE较安慰剂显著增加卵巢癌发病率(35例[0.041%] vs 17例[0.020%];HR 2.04,95%CI 1.14-3.65;P=0.014)和卵巢癌死亡率(P=0.006)。
- CEE联合MPA较安慰剂未增加卵巢癌发病率(75例[0.051%] vs 63例[0.045%];HR 1.14,95%CI 0.82-1.59;P=0.44)或卵巢癌死亡率。
- CEE联合MPA较安慰剂显著降低子宫内膜癌发病率(106例[0.073%] vs 140例[0.10%];HR 0.72,95%CI 0.56-0.92;P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Menopausal hormone therapy's influence on ovarian and endometrial cancers remains unsettled. Therefore, we assessed the long-term influence of conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) and CEE-alone on ovarian and endometrial cancer incidence and mortality in the Women's Health Initiative randomized, placebo-controlled clinical trials. MATERIALS AND METHODS: Postmenopausal women, age 50-79 years, were entered on two randomized clinical trials evaluating different menopausal hormone therapy regimens. In 16,608 women with a uterus, 8,506 were randomly assigned to once daily 0.625 mg of CEE plus 2.5 mg once daily of MPA and 8,102 placebo. In 10,739 women with previous hysterectomy, 5,310 were randomly assigned to once daily 0.625 mg of CEE-alone and 5,429 placebo. Intervention was stopped for cause before planned 8.5-year intervention after 5.6 years (CEE plus MPA) and after 7.2 years (CEE-alone). Outcomes include incidence and mortality from ovarian and endometrial cancers and deaths after these cancers. RESULTS: After 20-year follow-up, CEE-alone, versus placebo, significantly increased ovarian cancer incidence (35 cases [0.041%] v 17 [0.020%]; hazard ratio [HR], 2.04 [95% CI, 1.14 to 3.65]; P = .014) and ovarian cancer mortality (P = .006). By contrast, CEE plus MPA, versus placebo, did not increase ovarian cancer incidence (75 cases [0.051%] v 63 [0.045%]; HR, 1.14 [95% CI, 0.82 to 1.59]; P = .44) or ovarian cancer mortality but did significantly lower endometrial cancer incidence (106 cases [0.073%] v 140 [0.10%]; HR, 0.72 [95% CI, 0.56 to 0.92]; P = .01). CONCLUSION: In randomized clinical trials, CEE-alone increased ovarian cancer incidence and ovarian cancer mortality, while CEE plus MPA did not. By contrast, CEE plus MPA significantly reduced endometrial cancer incidence.
引用
- Chlebowski RT, Aragaki AK, Pan K, et al. Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials. J Clin Oncol. 2024. PMID: 39173088. doi:10.1200/JCO.23.01918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。